Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia
- PMID: 17136334
- DOI: 10.1007/s00508-006-0704-0
Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia
Abstract
Background and aim: Patients with advanced liver disease due to thrombocytopenia and chronic infection with hepatitis C virus (HCV) are difficult to treat in view of concerns about the efficacy and safety of interferon-based therapy. Nevertheless, antiviral therapy might have a substantial benefit in these patients as it potentially minimizes disease progression and prevents recurrence after liver transplantation. We evaluated the safety, efficacy and tolerability of standard interferon-alpha in an accelerating dose regimen in combination with ribavirin in patients with HCV-induced liver cirrhosis and thrombocytopenia.
Patients: Nine patients (M=8, age: 48.4 +/- 9.9, mean +/- SD) with HCV-related advanced liver disease and thrombocytopenia were prospectively investigated. The Child-Pugh stage was A in six patients and B in three, the MELD score was 11 [6-17] (median [range]). Four patients were interferon naive. HCV-genotype distribution was 1b (n=3), 3a (n=4) and 4 (n=2). The patients received 1-1.5 MU/d standard interferon-a2b with increasing dose regimen and weight-based ribavirin for 48 weeks (genotype 1), or 24 weeks (genotype 3), or until liver transplantation, respectively.
Results: The baseline platelet count was 64.3 +/- 8.7 (G/l, mean +/- SD) and remained remarkably stable during treatment (58.0 +/- 12.4 G/l at week 4, 51.7 +/- 20.5 G/l at week 8, P=0.1). All patients had adverse events such as weight loss, fever and anorexia. Hospitalization because of decompensation or infection was necessary in three patients. Three patients underwent liver transplantation. A virological response on treatment was achieved in eight patients and sustained in three (33.3%) patients.
Conclusion: Treatment with standard interferon-alpha2b/ribavirin could be of benefit in patients with advanced liver cirrhosis and thrombocytopenia however, a vigilant monitoring of these high risk patients is mandatory.
Similar articles
-
Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.Antivir Ther. 2008;13(5):663-73. Antivir Ther. 2008. PMID: 18771050 Clinical Trial.
-
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.Gastroenterology. 2014 Feb;146(2):442-52.e1. doi: 10.1053/j.gastro.2013.10.012. Epub 2013 Oct 12. Gastroenterology. 2014. PMID: 24126097 Clinical Trial.
-
A review of the treatment of chronic hepatitis C virus infection in cirrhosis.Clin Ther. 2010 Dec;32(13):2117-38. doi: 10.1016/S0149-2918(11)00022-1. Clin Ther. 2010. PMID: 21316532 Review.
-
Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus.Gut Liver. 2016 Jul 16;10(4):617-23. doi: 10.5009/gnl15193. Gut Liver. 2016. PMID: 26601828 Free PMC article.
-
Treatment of interferon-alpha for chronic hepatitis C.Expert Opin Pharmacother. 2006 Jun;7(9):1163-79. doi: 10.1517/14656566.7.9.1163. Expert Opin Pharmacother. 2006. PMID: 16732703 Review.
Cited by
-
Antiviral treatment of chronic hepatitis C in clinical routine.Wien Klin Wochenschr. 2010 Apr;122(7-8):237-42. doi: 10.1007/s00508-010-1364-7. Wien Klin Wochenschr. 2010. PMID: 20503023
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials